Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19103


Purpose:

This research trial studies tissue samples from patients with ovarian cancer in the laboratory. Analyzing tissue samples from patients in the laboratory may help doctors learn more about cancer.


Study summary:

OBJECTIVES: I. Utilize array comparative genomic hybridization and Taqman analyses, a quantitative genomic polymerase chain reaction, to validate the observation that a gain in chromosome 8q is predictive of shorter progression-free survival in patients with primary grade 2 or grade 3 advanced serous papillary ovarian cancer. II. Utilize these analyses to determine whether a gain in chromosome 8q is predictive of worse overall survival in these patients. III. Utilize these analyses to determine whether other previously identified chromosomal changes (3q gain, 7q gain, 16q loss, and 17pter-q21 loss) predict outcome in these patients and the association between these changes and clinical characteristics. IV. Utilize these analyses to identify up to 5 additional chromosomal changes and their association that may predict outcome (progression-free and overall survival) in these patients. OUTLINE: Genomic DNA is isolated from optimal cutting temperature (OCT)-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.


Criteria:

Inclusion Criteria: - Stage III or IV, high-grade (grade 2 or 3) ovarian cancers - No borderline or low-grade (grade 1) tumors - Tissue from predominately serous ovarian cancer only - No clear cell, endometrioid, mucinous, transitional cell, or mixed without predominant serous component - Tissue obtained during prior optimal or suboptimal cytoreductive surgery - Must be enrolled on GOG-0136 and a GOG front-line paclitaxel/platinum chemotherapy trial - Frozen tissue and hematoxylin-eosin stained section from the ovary obtained at initial surgery - Performance status - GOG 0-2


NCT ID:

NCT00053235


Primary Contact:

Principal Investigator
David Gershenson
Gynecologic Oncology Group


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19103
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.